Atlas Trials

Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients

Clinical trial NCT05167513 · COMPLETED

Trial details

NCT number
NCT05167513
Sponsor
Getz Pharma
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Quality of LifeType 2 DiabetesMetformin+Sitagliptin
Start date
2021-01-01
Primary completion
2022-04-28
Enrollment
188

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.